New Platinum Drug Effective Against Resistant Tumors
Author Information
Author(s): Pratesi G, Perego P, Polizzi D, Righetti S C, Supino R, Caserini C, Manzotti C, Giuliani F C, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
The novel triplatinum compound BBR 3464 is effective against cisplatin-resistant tumors, particularly those with p53 mutations.
Conclusion
The triplatinum complex BBR 3464 shows significant anti-tumor efficacy, especially in p53-mutant tumors, suggesting it may be a promising new treatment option.
Supporting Evidence
- The triplatinum compound BBR 3464 was effective against all tested tumors.
- It showed impressive efficacy, including complete tumor regressions in lung carcinoma models.
- BBR 3464 was more effective against p53-mutant tumors than those with the wild-type gene.
- Transfer of functional p53 reduced sensitivity to BBR 3464 but increased sensitivity to cisplatin.
- The compound induced apoptosis in lung carcinoma cells with mutant p53.
Takeaway
Scientists created a new type of platinum drug that works better on certain cancer cells that don't respond to regular treatments. It seems to work especially well on cells with a specific mutation.
Methodology
Preclinical studies were conducted on human tumor xenografts to assess the efficacy of the triplatinum compound.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website